Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KB-R7785 is a novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the inhibition of TNF-alpha production.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 2,120.00 | |
50 mg | 8-10 weeks | $ 2,780.00 | |
100 mg | 8-10 weeks | $ 3,700.00 |
Description | KB-R7785 is a novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the inhibition of TNF-alpha production. |
Molecular Weight | 349.42 |
Formula | C18H27N3O4 |
CAS No. | 168158-16-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KB-R7785 168158-16-5 L 739758 KB-R-7785 L739758 KB-R 7785 inhibitor inhibit